TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01985477
Drug: All-Trans Retinoic Acid (ATRA)
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days.
Study: NCT02865551
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Performance of epidural anesthesia by a certified anesthesiologist.
Study: NCT02367352
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib tablets
Study: NCT00127972
Drug: stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127972
Drug: lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02367352
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel intravenous solution
Study: NCT00226915
Drug: Paclitaxel+Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
Study: NCT00127972
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127972
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127972
Drug: trizivir
Normalized name: Trizivir
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00226915
Drug: Paclitaxel+Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
Study: NCT02639806
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02639806
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01667406
Drug: Kisspeptin 1.6nmol/kg
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single kisspeptin dose 1.6 nmol/kg subcutaneously
Study: NCT01667406
Drug: Kisspeptin 3.2nmol/kg
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single kisspeptin dose 3.2 nmol/kg subcutaneously
Study: NCT01667406
Drug: Kisspeptin 6.4nmol/kg
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single kisspeptin dose 6.4 nmol/kg subcutaneously
Study: NCT01667406
Drug: Kisspeptin 9.6nmol/kg
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single kisspeptin dose 9.6 nmol/kg subcutaneously
Study: NCT01667406
Drug: Kisspeptin 12.8nmol/kg
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single kisspeptin dose 12.8 nmol/kg subcutaneously
Study: NCT01667406
Drug: Kisspeptin 9.6 nmol/kg double
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
Study: NCT01667406
Drug: Kisspeptin 9.6 nmol/kg + saline
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
Study: NCT00079339
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03997058
Drug: Oral estazolam medication
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
Study: NCT02477397
Drug: Spiromax Budesonide/formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
Study: NCT02477397
Drug: Diskus Fluticasone/salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
Study: NCT02229578
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
Study: NCT01468532
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01468532
Drug: pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT01468532
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02034097
Drug: Foretinib
Normalized name: Foretinib
DrugBank: Foretinib (DB12307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
Study: NCT02034097
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
Study: NCT04500067
Drug: IVIG
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
Study: NCT01646385
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: use as per routine clinical practice
Study: NCT01777334
Drug: Umeclidinium/Vilanterol 62.5/25 mcg
Normalized name: umeclidinium/vilanterol 62.5/25 MCG/INHAL Dry Powder Inhaler, 7 Blisters
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation Powder
Study: NCT01777334
Drug: Tiotropium 18 mcg
Normalized name: tiotropium 18 MCG Inhalation Powder
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder
Study: NCT03019081
Drug: Isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
Study: NCT00466713
Drug: Rosiglitazone therapy
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02045290
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
Study: NCT04042077
Drug: Delafloxacin
Normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
Study: NCT04042077
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
Study: NCT04042077
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
Study: NCT04042077
Drug: Piperacillin/Tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
Study: NCT02103114
Drug: Anti-thrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4~* expressed as a % normal level based on functional ATIII assay
Study: NCT03004404
Drug: BI 730357
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for reconstitution of an oral solution (PfoS)
Study: NCT03004404
Drug: BI 730357
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 730357 film-coated tablet
Study: NCT00335205
Drug: ropinirole
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02552459
Drug: dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
Study: NCT02552459
Drug: dexmedetomidine 2
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
Study: NCT00660920
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different dosages of drug given orally once per day.
Study: NCT00749801
Drug: Nattokinase
Normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules in the morning and before bed-time daily
Study: NCT01744925
Drug: Icotinib of routine dose
Normalized name: OIL OF CAMPHOR
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib: 125mg, oral administration, three times per day.
Study: NCT01744925
Drug: Icotinib of high dose
Normalized name: high-density polyethylene
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib: 375mg, oral administration, three times per day.
Study: NCT02552459
Drug: dexmedetomidine 3
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
Study: NCT01238536
Drug: Epidural steroid injection
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
Study: NCT03077620
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
Study: NCT00309608
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin medium dose tablet once daily
Study: NCT00309608
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin high dose tablet once daily
Study: NCT00309608
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin low dose tablet once daily
Study: NCT00309608
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride tablets once daily
Study: NCT00004430
Drug: Dihematoporphyrin derivative
Normalized name: dihematoporphyrin ether
DrugBank: Dihematoporphyrin ether (DB15351)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004438
Drug: leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03240939
Drug: Dutasteride 0.5 mg
Normalized name: dutasteride 0.5 MG
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT03240939
Drug: Tadalafil 5 mg
Normalized name: tadalafil 5 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT03240939
Drug: YY-201
Normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00991822
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00991822
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01530737
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
Study: NCT01080300
Drug: Gabapentin Extended Release
Normalized name: gabapentin Extended Release Oral Tablet
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin ER 1800mg daily
Study: NCT04467892
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
Study: NCT04467892
Drug: Methyl Prednisolonate
Normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
Study: NCT02327624
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study: NCT02327624
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study: NCT02327624
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study: NCT00429494
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
Study: NCT00675324
Drug: Laxabon
Normalized name: Petrolatum 214.2 mg in 1 g / Mineral Oil 33.8 mg in 1 g ORAL GEL [Laxatone]
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
Study: NCT00975221
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
Study: NCT02818660
Drug: Synachten
Normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To stimulate the adrenals to increase the cortisol Production as much as possible
Study: NCT04358341
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 ivdrip every 14 days
Study: NCT01099917
Drug: Maitake
Normalized name: Maitake
DrugBank: Grifola frondosa whole (DB19262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test.
Study: NCT02799355
Drug: Sofosbuvir, Ribavirin, With or Without Pegylated Interferon
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
Study: NCT01263509
Drug: Alogliptin and voglibose
Normalized name: metformin and alogliptin
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study: NCT01364402
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 50,000U intravenously
Study: NCT03393403
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
Study: NCT03393403
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.125ml/kg intravenously infusion in Dexmedetomidine_adj group and control group
Study: NCT01263509
Drug: Alogliptin and voglibose
Normalized name: metformin and alogliptin
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study: NCT04430166
Drug: PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg / intravenous drip, once every three weeks
Study: NCT00422734
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg tadalafil tablet taken by mouth once a day for 12 weeks
Study: NCT04530578
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Enoxaparine every 24 hours
Study: NCT04544228
Drug: bupivacaine +ketamine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
Study: NCT04544228
Drug: bupivacaine + neostigmine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
Study: NCT04544228
Drug: bupivacaine +saline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
Study: NCT00508209
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
Study: NCT04489108
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
Study: NCT01031498
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
Study: NCT01031498
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy.
Study: NCT02688530
Drug: IV Dexamethasone 4mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02688530
Drug: IV Dexamethasone 6mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02688530
Drug: IV Dexamethasone 8mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00763451
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT00763451
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT00065624
Drug: lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04275180
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban plus standard medical treatment